 |
|
|
|
 |
|
|
| Article 1 to 10 out of 35 concerning Alnylam Pharmaceuticals, Inc.
|
-
Alnylam Announces Close of Investment and Expanded Agreement Related to the Tekmira-Protiva Business Combination
(06/05/2008)
Agreement Expands Alnylam's Access to Key Technologies and Intellectual Property for Systemic Delivery of RNAi Therapeutics
Alnylam Pharmaceuticals, Inc. announced the closing of its investment in and completion of its expanded agreement with Tekmira Pharmaceuticals Corporation as a result of the achievement of Tekmira's business combination with Protiva Biotherapeutics ...
-
Alnylam and Collaborators at MIT Publish Research on the Discovery of 'Lipidoids'
(05/02/2008)
Novel Class of Lipid-Based Molecules for the Delivery of RNAi Therapeutics
Alnylam Pharmaceuticals, Inc. announced the publication of a new study in Nature Biotechnology by Alnylam scientists and collaborators from the David H. Koch Institute for Integrative Cancer Research at the Massachusetts Institute of Technology ...
-
Alnylam and Medtronic Advance Collaboration on Drug-Device Combinations with RNAi Therapeutics for CNS Diseases
(08/01/2007)
Collaboration Focuses on RNAi Therapeutic Program for Huntington's Disease
Medtronic, Inc. and Alnylam Pharmaceuticals, Inc. announced that the companies are advancing their collaboration initiated in February, 2005, following positive pre-clinical data generated under the initial joint technology development phase of the ...
-
Roche and Alnylam form major alliance on RNAi therapeutics
(07/10/2007)
Alnylam to receive 331 million US dollars in upfront payments and equity investment
Roche and the US-based biopharmaceutical company Alnylam Pharmaceuticals, Inc. announced that they have entered into a major alliance in which Roche obtains a non-exclusive license to Alnylam's technology platform for developing RNAi (RNA ...
-
Alnylam Grants Bio-Rad License to Kreutzer-Limmer Patents for the RNA Interference (RNAi) Research Products Market
(04/03/2007)
Alnylam Pharmaceuticals, Inc. announced today that it has granted Bio-Rad a non-exclusive license to provide RNAi research products under the Kreutzer-Limmer patent family. This patent family, owned exclusively by Alnylam, covers small interfering ...
-
INEX and Alnylam Announce Allowance of New U.S. Patent Covering Delivery of RNAi Therapeutics
(03/09/2007)
New Patent Broadly Covers Delivery of RNAi Therapeutics with Cationic Liposomes
Inex Pharmaceuticals Corporation and Alnylam Pharmaceuticals, Inc. announced that the United States Patent and Trademark Office (USPTO) has allowed claims in a patent application that covers nucleic acid-lipid compositions, including cationic ...
-
Alnylam and Isis Announce Allowance of First U.S. Patent Covering Human microRNAs
(03/05/2007)
Alnylam Pharmaceuticals, Inc. and Isis Pharmaceuticals, Inc. announced that the United States Patent and Trademark Office (USPTO) has allowed claims in a patent application that covers microRNAs (miRNAs) and therapeutic molecules that target these ...
-
Isis and Alnylam Announce Issued U.S. Patent Broadly Covering Chemical Modifications of Oligonucleotide Therapeutics
(11/29/2006)
Isis Pharmaceuticals, Inc. and Alnylam Pharmaceuticals, Inc. announced that a key patent was issued by the United States Patent and Trademark Office (USPTO). The U.S. patent (No. 7,138,517 or " '517 patent") broadly covers certain chemical ...
-
Alnylam and Yale University Scientists Demonstrate Therapeutic Silencing of Disease Target
(11/08/2006)
Alnylam Pharmaceuticals, Inc. announced publication of data demonstrating that an RNAi therapeutic can silence angiopoietin 2 (Ang2), a key mediator in acute lung injury. In a paper published in Nature Medicine, scientists from Yale University and ...
-
Biogen Idec and Alnylam Alliance to Develop Therapeutics for Treatment of Progressive Multifocal Leukoencephalopathy (PML)
(09/22/2006)
Biogen Idec and Alnylam Pharmaceuticals, Inc. announced a collaboration to discover and develop RNAi therapeutics for the potential treatment of progressive multifocal leukoencephalopathy (PML). PML is caused by infection of the central nervous ...
|
|
|
|
|
Top